Corbus Pharmaceuticals Holdings, Inc. Net Investment Income
Corbus Pharmaceuticals Holdings, Inc. (CRBP) reported Net Investment Income of $1.16 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:NetInvestmentIncome · last filed 2026-08-06
- Corbus Pharmaceuticals Holdings, Inc. net investment income for the quarter ending 2026-06-30 was $1.16M, a 11.42% decline year-over-year.
- Corbus Pharmaceuticals Holdings, Inc. net investment income for the quarter ending 2026-03-31 was $1.40M, a 16.60% decline year-over-year.
- Corbus Pharmaceuticals Holdings, Inc. net investment income for the quarter ending 2025-12-31 was $1.41M, a 20.79% decline year-over-year.
- Corbus Pharmaceuticals Holdings, Inc. net investment income for the quarter ending 2025-09-30 was $1.13M, a 40.88% decline year-over-year.
- Corbus Pharmaceuticals Holdings, Inc. net investment income for fiscal 2025 was $5.53M, a 12.38% decline from fiscal 2024.
- Corbus Pharmaceuticals Holdings, Inc. net investment income for fiscal 2024 was $6.31M, a 285.76% increase from fiscal 2023.
- Corbus Pharmaceuticals Holdings, Inc. net investment income for fiscal 2023 was $1.64M.
| Period end | Net Investment Income 3 month | Net Investment Income 6 month | Net Investment Income 9 month | Net Investment Income 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.16M 10-Q · filed 2026-08-06 | $2.57M 10-Q · filed 2026-08-06 | $3.98M derived: sum of 3 quarters · filed 2026-08-06 | $5.10M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $1.40M 10-Q · filed 2026-05-12 | $2.81M derived: sum of 2 quarters · filed 2026-05-12 | $3.94M derived: sum of 3 quarters · filed 2026-05-12 | $5.25M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $1.41M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $2.54M derived: sum of 2 quarters · filed 2026-03-09 | $3.85M derived: sum of 3 quarters · filed 2026-08-06 | $5.53M 10-K · filed 2026-03-09 |
| 2025-09-30 | $1.13M 10-Q · filed 2025-11-12 | $2.44M derived: sum of 2 quarters · filed 2026-08-06 | $4.12M 10-Q · filed 2025-11-12 | $5.90M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $1.31M 10-Q · filed 2026-08-06 | $3.00M 10-Q · filed 2026-08-06 | $4.78M derived: sum of 3 quarters · filed 2026-08-06 | $6.68M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $1.68M 10-Q · filed 2026-05-12 | $3.46M derived: sum of 2 quarters · filed 2026-05-12 | $5.36M derived: sum of 3 quarters · filed 2026-05-12 | $6.96M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $1.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $3.68M derived: sum of 2 quarters · filed 2026-03-09 | $5.28M derived: sum of 3 quarters · filed 2026-03-09 | $6.31M 10-K · filed 2026-03-09 |
| 2024-09-30 | $1.90M 10-Q · filed 2025-11-12 | $3.50M derived: sum of 2 quarters · filed 2025-11-12 | $4.53M 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $1.60M 10-Q · filed 2025-08-05 | $2.63M 10-Q · filed 2025-08-05 | ||
| 2024-03-31 | $1.03M 10-Q · filed 2025-05-06 | |||
| 2023-12-31 | $1.64M 10-K · filed 2025-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |